New cocktail aims to shrink Hard-to-Treat colon tumors
NCT ID NCT05999812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of three drugs—ATRA (a vitamin A derivative), bevacizumab (a blood vessel growth blocker), and atezolizumab (an immunotherapy)—in 22 people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this mix can shrink tumors or stop them from growing. Participants receive ATRA pills at home and the other two drugs through an IV every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- all-trans-retinoic acid (ATRA), bevacizumab, and atezolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced colorectal cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 22 participants, so results may not apply to a larger population. The combination may cause significant side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?